Gofex

Primary dysmenorrhea. Relief of headache, pain after tooth extraction, post-op pain; signs & symptoms of RA & OA. Musculoskeletal & traumatic alterations implying pain & inflammation.

Adult 1,200 mg daily, divided in 3-4 doses. RA Max daily dose: 2,400 mg. Primary dysmenorrhea 400 mg every 4 hr.

Should be taken with food: May drink concomitantly w/ some milk or during meals to reduce gastric disturbances.

Hypersensitivity to ibuprofen, ASA or other NSAIDs. History of GI bleeding or perforation. Active or history of recurrent peptic ulcer/haemorrhage. Other active bleeding eg, cerebrovascular bleeding or colitis ulcerosa. Hemorrhagic diathesis. Severe heart failure (NYHA Class IV). Severe kidney &/or liver insufficiency. 3rd trimester of pregnancy.

Discontinue at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity; visual disturbances. W/draw treatment when GI bleeding or ulceration occurs. Contraindicated in peri-op pain in the setting of CABG surgery. Avoid concomitant use w/ NSAIDs including COX-2 selective inhibitors; high doses in patients w/ uncontrolled HTN, CHF (NYHA II-III), established ischaemic heart disease, peripheral arterial disease &/or cerebrovascular disease. Consider combination therapy w/ misoprostol or PPIs in patients w/ history of ulcer, elderly or those requiring concomitant low dose aspirin or other drugs likely to increase GI risk. Careful consideration before initiating long-term treatment in patients w/ CV events risk factors (eg, HTN, hyperlipidaemia, DM & smoking). Appropriate monitoring in patients w/ history of HTN &/or mild to moderate CHF. Increased risk of serious CV thrombotic events, MI & stroke. Patients w/ history of GI disease (eg, ulcerative colitis, Crohn's disease); coagulation disorders, cardiac insufficiency; considerable dehydration; SLE or other collagen diseases. May mask symptoms of infection. Risk of long-term habitual use. Bronchospasm may be precipitated in patients suffering from or w/ previous history of bronchial asthma or allergic disease. May produce an increase in LFT results. Has minor influence on the ability to drive & operate machine. Liver or kidney insufficiency. Dose should be kept as low & shortest duration in women attempting to conceive. 1st & 2nd trimester of pregnancy. Elderly.

Dyspepsia, diarrhoea. Headache, dizziness; abdominal pain, nausea, flatulence; skin disorder, rash.

Potential increased adverse effects w/ ASA. Decreased efficacy of furosemide & thiazide diuretics. Increased risk of GI ulceration or bleeding w/ corticosteroid; antiplatelet agents & SSRIs. Enhanced effects of anticoagulants eg, warfarin. Diminished effects of antihypertensives. Risk of acute renal failure w/ ACE inhibitors or β-blocking agents. Increased plasma level of digoxin, phenytoin & lithium. Increased MTX plasma level. Increased risk of haemarthrosis & haematoma in HIV + haemophilic patients w/ zidovudine. Increased risk of nephrotoxicity w/ tacrolimus. Increased hypoglycemic effects of oral hypoglycemic agents & insulin. Increased risk of cyclosporine nephrotoxicity effect. Increased exposure & plasma conc w/ voriconazole or fluconazole. Increased risk of seizure w/ quinolone antibiotics. Potentiated risk of bleeding w/ gingko biloba. Decreased excretion of aminoglycosides. May affect diagnostic test results (eg, prolonged bleeding time; decreased serum glucose conc, CrCl, haematocrit or Hb; increased BUN, serum creatinine conc & kaliemia; elevation of transaminases).

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AE01 - ibuprofen ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.

K